A longitudinal cohort study of people who have used injectable medicines found that those who inject the medicine (PWID) are being treated for hepatitis C virus (HCV). This is associated with a significant reduction in liver disease and mortality. According to the author, with continuous testing, treatment, and community-based intervention, the United States will remove HCV in 2030 set by the World Health Organization (WHO) and the US Department of Health and Human Services (HHS) within the next decade. You may approach your goal. ..The survey results are published at Annual report of internal medicine.
HCV is curable in 95% of cases. The challenge is to identify people in the area infected with HCV and link them to care and treatment. In high-income areas such as the United States, most people who are chronically infected with HCV are PWIDs who face structural barriers to both testing and treatment of HCV. They also carry an unbalanced burden of comorbidities such as HIV and alcohol use disorders, which can significantly change the net effect of HCV treatment on mortality.
Researchers at the Johns Hopkins Bloomberg School of Public Health surveyed 1,323 participants enrolled in the ALIVE (AIDS Linked to the IntraVenous Experience) study in Baltimore, Maryland from 2006 to 2019, with all-oral HCV treatment being PWID. We evaluated whether they were accessed by and whether their treatment was reduced. Liver disease burden and mortality. All participants studied were chronic HCV infections. They were tested for HCV RNA every other year from 2006 to 2012 and annually from 2014 to 2019.
Researchers have found that the proportion of participants with HCV RNA found has dropped significantly from 100% of participants in 2006 to 48% in 2019, resulting in a significant increase in treatment. At the same time, they observed a strong association between this decrease in HCV RNA and liver disease. During this same period, cirrhosis decreased from being present in 15% of participants in 2006 and 8% in 2019.
Given that 48% of the participants in the sample remain chronically infected, according to the authors, their findings are to eliminate treatment intake heterogeneity between PWIDs and HCV infection in the United States. It also emphasizes that it is essential to overcome these residual barriers. Also, the goal of reducing mortality by 65% by 2030 is compared to 2015, so progress towards achieving this goal should include HCV epidemiological data collected prior to 2015. He also added that there is.
Effect of uptake of hepatitis C treatment on cirrhosis and mortality in drug-injected individuals Annual report of internal medicine (2022). DOI: 10.7326 / M21-3846
American College of Physicians
Quote: Access to hep C treatment (July 11, 2022) to reduce morbidity and mortality in people who inject drugs is https: //medicalxpress.com/news/2022-07-access-hep-treatment Obtained July 11, 2022 from -morbidity-mortality. html
This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. Content is provided for informational purposes only.
Access to hepatitis C treatment to reduce morbidity and mortality in people who inject drugs
Source link Access to hepatitis C treatment to reduce morbidity and mortality in people who inject drugs